CDKN2A deletions are associated with poor outcomes in 101 adults with T‐cell acute lymphoblastic leukemia

Huan‐Ping Wang; Yi‐Le Zhou; Xin Huang; Jie‐Jing Qian; Jian‐Hu Li; Xue‐Ying Li; Chen‐Ying Li; Yin‐Jun Lou; Wen‐Yuan Mai; Hai‐Tao Meng; Wen‐Juan Yu; Hong‐Yan Tong; Jie Jin; Hong‐Hu Zhu

doi:10.1002/ajh.26069

journal article Dec 24, 2020

CDKN2A deletions are associated with poor outcomes in 101 adults with T‐cell acute lymphoblastic leukemia

Huan‐Ping Wang

Yi‐Le Zhou

Xin Huang

Jie‐Jing Qian Jian‐Hu Li Xue‐Ying Li

Chen‐Ying Li Yin‐Jun Lou Wen‐Yuan Mai Hai‐Tao Meng Wen‐Juan Yu Hong‐Yan Tong Jie Jin

Hong‐Hu Zhu

American Journal of Hematology Vol. 96 No. 3 pp. 312-319 · Wiley

View at Publisher Save 10.1002/ajh.26069

Abstract

AbstractThe identification of genetic risk subgroups of T‐cell acute lymphoblastic leukemia (T‐ALL) may provide evidence for risk stratification and individualized treatment. We investigated the characteristics and prognostic value of tumor suppressor gene CDKN2A deletions in 101 patients with T‐ALL. The CDKN2A deletion was present in 23% (23/101) of T‐ALL by fluorescence in situ hybridization (FISH). The most common type of CDKN2A deletion was homozygous deletion (70%, 16/23). A lower frequency of CDKN2A deletion was found in patients with early T‐cell precursor (ETP) ALL than in patients with non‐ETP‐ALL (10.4% vs 34.0%; P = .008). Deletion of CDKN2A was significantly associated with younger age (P = .001), higher white blood cell (WBC) count (P < .001) and higher lactate dehydrogenase (LDH) level (P = .002). Patients with CDKN2A deletion had lower 2‐year overall survival (OS) and event‐free survival (EFS) rates than patients without CDKN2A deletion (2‐year OS: 18.6% ± 8.9% vs 47.4% ± 6.2%, P = .032; EFS: 16.4 ± 8.3 vs 38.6 ± 5.9%, P = .022). In multivariable analysis, CDKN2A deletion was an independent adverse prognostic factor for OS (P = .016). In conclusion, adult T‐ALL patients with CDKN2A deletion had a poor prognosis, and these patients might benefit from intensive chemotherapy or allogeneic hematopoietic stem‐cell transplantation.

Topics

No keywords indexed for this article. Browse by subject →

References

27

[1]

10.1182/blood-2016-07-692608

[2]

10.1007/s11899-018-0455-9

[3]

10.1200/jco.2012.48.5292

[4]

10.1002/cam4.2757

[5]

10.1002/pbc.27001

[6]

10.1182/blood.v89.11.4161

[7]

10.1182/blood.v97.2.572

[8]

10.1182/blood.v99.7.2620

[9]

10.1182/blood-2017-07-796862

[10]

10.1186/s13045-016-0270-5

[11]

10.1158/1078-0432.ccr-11-1227

[12]

10.1186/s13045-018-0639-8

[13]

10.1182/blood-2013-03-491092

[14]

10.2217/pgs-2016-0075

[15]

10.1016/j.leukres.2016.03.002

[16]

Chinese Society of Hematology CMA, Society of Hematological Malignancies Chinese Anti‐Cancer A "A Chinese expert panel consensus on diagnosis and treatment of adult acute lymphoblastic leukemia" Zhonghua Xue Ye Xue Za Zhi (2012)

[17]

10.1002/cncr.20668

[18]

10.1182/blood-2014-04-571570

[19]

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

Nitin Jain, Audrey V. Lamb, Susan O’Brien et al.

Blood 10.1182/blood-2015-08-661702

[20]

10.1016/s1470-2045(08)70314-0

[21]

10.1182/blood-2008-07-166801

[22]

10.7150/jca.11959

[23]

10.3324/haematol.2019.225078

[24]

10.1186/s13045-015-0138-0

[25]

10.1038/bcj.2011.49

[26]

Liao HY "Outcome of 126 adolescent and adult T‐cell acute leukemia/lymphoma patients and the prognostic significance of early T‐cell precursor leukemia subtype" Zhonghua Xue Ye Xue Za Zhi (2019)

[27]

Gong XY "Characteristics and prognosis in adult patients with early T‐cell precursor acute lymphoblastic leukemia" Zhonghua Xue Ye Xue Za Zhi (2018)

Cited By

32

CDKN2A alternations in non-small cell lung cancer: An evaluation using next-generation sequencing

Xu Feng, Heng Chang · 2025

Pathology - Research and Practice

Metrics

32

Citations

27

References

Details

Published: Dec 24, 2020
Vol/Issue: 96(3)
Pages: 312-319
License: View

Authors

H

Huan‐Ping Wang